Genotoxicity Testing Shows 7-OH-Enriched Kratom Preparation Lacks Significant Genetic Hazard

Why it matters

As 7-OH products proliferate in the U.S. market, understanding their safety profile at the genetic level is critical for public health policy. This first comprehensive in vitro genotoxicity assessment provides empirical evidence about mutation and chromosome damage risks.

The big picture

Regulatory agencies and policymakers have focused on 7-hydroxymitragynine as a public health threat due to its potency and addiction potential. However, safety data on genotoxicity (DNA damage) has been sparse. This integrated computational and laboratory study applies rigorous OECD testing guidelines to assess whether the alkaloids and kratom preparations pose genetic hazards, which would trigger stricter controls.

Key findings

• In silico modeling predicted no genotoxic activity for major kratom alkaloids (mitragynine, 7-hydroxymitragynine, speciogynine, paynantheine). OECD micronucleus testing showed a weak positive response only at the highest, cytotoxic concentration (125 µg/mL) in human TK6 cells. Ames bacterial reverse mutation test was negative across five strains at up to 5000 µg/plate. The weight of evidence—negative predictions, negative Ames results, limited in vitro micronucleus response—suggests the 7-OH-enriched preparation does not present significant genotoxic hazard under tested conditions.

What they say

"While a weak positive chromosomal effect was noted at a highly cytotoxic concentration, the overall weight of evidence suggests that this 7-OHMG-enriched Kratom preparation does not present a significant genotoxic hazard under the conditions tested." — Study authors (2026)

Bottom line

**A comprehensive genotoxicity assessment found 7-OH-enriched kratom showed no significant genetic damage risk at physiologically relevant doses, though higher-dose toxicity prevents full evaluation.**